103 results about "Carbidopa" patented technology

Disclosed are substances, compositions, dosage forms and methods that comprise levodopa and / or carbidopa.

The present invention relates to stable compositions of levodopa and carbidopa, methods of treating patients with these compositions, and methods of preparing these compositions.

The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and / or levodopa. The extended release composition in the tablet excludes a release rate-controlling polymer, and a release rate-controlling coating; however, the release of the carbidopa and / or levodopa is independently optionally delayed for a lag time. The invention also provides a tablet having a extended release form of levodopa and a rapid or immediate release form of carbidopa. A tablet can contain levodopa present in extended release form and rapid or immediate release form, and carbidopa present in extended release form and rapid or immediate release form. The tablet is used to treat Parkinson's disease and other movement related disorders, diseases or syndromes.

The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further comprising an organic acid. A subject of the invention is also a process for preparing the composition, comprising granulation, in particular in a fluidized bed, of the various components and compression of the granules obtained.

The present invention relates to stable compositions of levodopa and carbidopa, methods of treating patients with these compositions, and methods of preparing these compositions.

The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further comprising an organic acid. A subject of the invention is also a process for preparing the composition, comprising granulation, in particular in a fluidized bed, of the various components and compression of the granules obtained.

The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.

The present invention refers to a solid pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable salts thereof characterized in that entacapone is in the form of granules and it is added separately to levodopa and carbidopa. In addition, this invention provides the process for its preparation.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

The invention discloses a levodopa / carbidopa compound sustained-release suspension and a preparation method thereof. The preparation comprises the following components in percentage by weight: 10-50% of levodopa, 10-50% of carbidopa and 10-50% of accessory realizing a sustained-release effect. Compared with a solid preparation, the suspension disclosed by the invention has the advantages that the drug is coated in resin so that the drug stability is improved; the suspension can be taken in divided dose, so that the problem that the oral solid sustained-release preparation prepared from large-dose drugs is hard to swallow is solved; in a multi-unit drug release system, the drug release action is the total of the drug release actions of particles, and the reproducibility and consistency are better; the phenomenon of excessively high local concentration often caused after the oral solid sustained-release preparation is ground can be avoided; the bad smell of the drug can be covered, and the palatability of the preparation is improved. The sustained-release preparation disclosed by the invention is to be clinically used as an anti-paralysis agitans drug.

A method of treating Parkinson's Disease comprising intestinally administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising levodopa and optionally carbidopa continuously over a period of greater than 16 hours.

The present invention relates to stable dosage forms and compositions of levodopa and carbidopa for the treatment of patients suffering from Parkinson's disease. The dosage forms and compositions comprise both solid and liquid formulations and result in stable pharmaceutical products. Such dosage forms and compositions comprise a metal chelator and a levodopa concentration from about 1 mg / mL to about 30 mg / mL.

Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.